

ISCTM BPSD Apathy Working Group Summary
16th Annual Meeting
21 February 2020

At our last BPSD Apathy WG meeting at the February ISCTM in Washington, DC, the following transpired:

The co-Chairs provided an update on the new diagnostic criteria wording for Apathy in Neurocognitive Disorders that was finalized at the 2019 AAIC. The paper that describes the process leading to and the outcome of that effort is in preparation and will be circulated to the WG for review. The FDA WG representatives, who have been involved with this effort from the start, have agreed to write an accompanying commentary.

Additional discussion topics included 1) Scale Development – whether development should be de novo, or be a derivation of currently existing scales. Either way, it should be able to have the ability to focus on each diagnostic domain, 2) Operationalizing the new criteria – utilizing our broader network (ie – the NPS-PIA and IPA) will be key here, and 3) Deciding on next steps and important areas to address in order to help the field of drug development for apathy in neurocognitive disorders.